Hosted on MSN2mon
Potential acquisition of Scorpion positive for Relay, says Barclaysgiven their similar competitive PI3Kalpha programs in breast cancer. Relay’s RLY-2608 is ahead in clinical development and Scorpion’s $2.5B acquisition value suggests upside in Relay shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback